CompletedPHASE2, PHASE3NCT02588677

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AB Science
Principal Investigator
Jesus S Mora, MD
Unidad de ELA, Hospital San Rafael, c/ Serrano, 199, 28016 Madrid, Spain
Intervention
Masitinib (4.5)(drug)
Enrollment
394 enrolled
Eligibility
18-75 years · All sexes
Timeline
20132018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02588677 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials